Engel, Christoph

[["dc.bibliographiccitation.issue","14"],["dc.bibliographiccitation.journal","Cancers"],["dc.bibliographiccitation.volume","14"],["dc.contributor.affiliation","Dumont, Martine; 1Genomics Center, CHU de Québec-Université Laval Research Center, 2705 Laurier Boulevard, Quebec City, QC GIV 4G2, Canada; martine.dumont@crchudequebec.ulaval.ca (M.D.); charles.joly-beauparlant@crchudequebec.ulaval.ca (C.J.-B.); arnaud.droit@crchudequebec.ulaval.ca (A.D.); stephane.dubois@crchudequebec.ulaval.ca (S.D.); annie-c.c-deschesnes@crchudequebec.ulaval.ca (A.-C.C.-D.); penny.soucy@crchudequebec.ulaval.ca (P.S.); maxime.vallee@chu-lyon.fr (M.V.); frederic.fournier.4@ulaval.ca (F.F.); audrey@mims.ai (A.L.)"],["dc.contributor.affiliation","Weber-Lassalle, Nana; 2Center for Familial Breast and Ovarian Cancer, Center for Integrated Oncology (CIO), Faculty of Medicine and University Hospital Cologne, University of Cologne, 50937 Cologne, Germany; nana.weber-lassalle@uk-koeln.de (N.W.-L.); corinna.ernst@uk-koeln.de (C.E.); rita.schmutzler@uk-koeln.de (R.K.S.); eric.hahnen@uk-koeln.de (E.H.)"],["dc.contributor.affiliation","Joly-Beauparlant, Charles; 1Genomics Center, CHU de Québec-Université Laval Research Center, 2705 Laurier Boulevard, Quebec City, QC GIV 4G2, Canada; martine.dumont@crchudequebec.ulaval.ca (M.D.); charles.joly-beauparlant@crchudequebec.ulaval.ca (C.J.-B.); arnaud.droit@crchudequebec.ulaval.ca (A.D.); stephane.dubois@crchudequebec.ulaval.ca (S.D.); annie-c.c-deschesnes@crchudequebec.ulaval.ca (A.-C.C.-D.); penny.soucy@crchudequebec.ulaval.ca (P.S.); maxime.vallee@chu-lyon.fr (M.V.); frederic.fournier.4@ulaval.ca (F.F.); audrey@mims.ai (A.L.)"],["dc.contributor.affiliation","Ernst, Corinna; 2Center for Familial Breast and Ovarian Cancer, Center for Integrated Oncology (CIO), Faculty of Medicine and University Hospital Cologne, University of Cologne, 50937 Cologne, Germany; nana.weber-lassalle@uk-koeln.de (N.W.-L.); corinna.ernst@uk-koeln.de (C.E.); rita.schmutzler@uk-koeln.de (R.K.S.); eric.hahnen@uk-koeln.de (E.H.)"],["dc.contributor.affiliation","Droit, Arnaud; 1Genomics Center, CHU de Québec-Université Laval Research Center, 2705 Laurier Boulevard, Quebec City, QC GIV 4G2, Canada; martine.dumont@crchudequebec.ulaval.ca (M.D.); charles.joly-beauparlant@crchudequebec.ulaval.ca (C.J.-B.); arnaud.droit@crchudequebec.ulaval.ca (A.D.); stephane.dubois@crchudequebec.ulaval.ca (S.D.); annie-c.c-deschesnes@crchudequebec.ulaval.ca (A.-C.C.-D.); penny.soucy@crchudequebec.ulaval.ca (P.S.); maxime.vallee@chu-lyon.fr (M.V.); frederic.fournier.4@ulaval.ca (F.F.); audrey@mims.ai (A.L.)"],["dc.contributor.affiliation","Feng, Bing-Jian; 3Department of Dermatology, University of Utah, Salt Lake City, UT 84103, USA; bingjian.feng@hsc.utah.edu (B.-J.F.); david.goldgar@hsc.utah.edu (D.E.G.)"],["dc.contributor.affiliation","Dubois, Stéphane; 1Genomics Center, CHU de Québec-Université Laval Research Center, 2705 Laurier Boulevard, Quebec City, QC GIV 4G2, Canada; martine.dumont@crchudequebec.ulaval.ca (M.D.); charles.joly-beauparlant@crchudequebec.ulaval.ca (C.J.-B.); arnaud.droit@crchudequebec.ulaval.ca (A.D.); stephane.dubois@crchudequebec.ulaval.ca (S.D.); annie-c.c-deschesnes@crchudequebec.ulaval.ca (A.-C.C.-D.); penny.soucy@crchudequebec.ulaval.ca (P.S.); maxime.vallee@chu-lyon.fr (M.V.); frederic.fournier.4@ulaval.ca (F.F.); audrey@mims.ai (A.L.)"],["dc.contributor.affiliation","Collin-Deschesnes, Annie-Claude; 1Genomics Center, CHU de Québec-Université Laval Research Center, 2705 Laurier Boulevard, Quebec City, QC GIV 4G2, Canada; martine.dumont@crchudequebec.ulaval.ca (M.D.); charles.joly-beauparlant@crchudequebec.ulaval.ca (C.J.-B.); arnaud.droit@crchudequebec.ulaval.ca (A.D.); stephane.dubois@crchudequebec.ulaval.ca (S.D.); annie-c.c-deschesnes@crchudequebec.ulaval.ca (A.-C.C.-D.); penny.soucy@crchudequebec.ulaval.ca (P.S.); maxime.vallee@chu-lyon.fr (M.V.); frederic.fournier.4@ulaval.ca (F.F.); audrey@mims.ai (A.L.)"],["dc.contributor.affiliation","Soucy, Penny; 1Genomics Center, CHU de Québec-Université Laval Research Center, 2705 Laurier Boulevard, Quebec City, QC GIV 4G2, Canada; martine.dumont@crchudequebec.ulaval.ca (M.D.); charles.joly-beauparlant@crchudequebec.ulaval.ca (C.J.-B.); arnaud.droit@crchudequebec.ulaval.ca (A.D.); stephane.dubois@crchudequebec.ulaval.ca (S.D.); annie-c.c-deschesnes@crchudequebec.ulaval.ca (A.-C.C.-D.); penny.soucy@crchudequebec.ulaval.ca (P.S.); maxime.vallee@chu-lyon.fr (M.V.); frederic.fournier.4@ulaval.ca (F.F.); audrey@mims.ai (A.L.)"],["dc.contributor.affiliation","Vallée, Maxime; 1Genomics Center, CHU de Québec-Université Laval Research Center, 2705 Laurier Boulevard, Quebec City, QC GIV 4G2, Canada; martine.dumont@crchudequebec.ulaval.ca (M.D.); charles.joly-beauparlant@crchudequebec.ulaval.ca (C.J.-B.); arnaud.droit@crchudequebec.ulaval.ca (A.D.); stephane.dubois@crchudequebec.ulaval.ca (S.D.); annie-c.c-deschesnes@crchudequebec.ulaval.ca (A.-C.C.-D.); penny.soucy@crchudequebec.ulaval.ca (P.S.); maxime.vallee@chu-lyon.fr (M.V.); frederic.fournier.4@ulaval.ca (F.F.); audrey@mims.ai (A.L.)"],["dc.contributor.affiliation","Fournier, Frédéric; 1Genomics Center, CHU de Québec-Université Laval Research Center, 2705 Laurier Boulevard, Quebec City, QC GIV 4G2, Canada; martine.dumont@crchudequebec.ulaval.ca (M.D.); charles.joly-beauparlant@crchudequebec.ulaval.ca (C.J.-B.); arnaud.droit@crchudequebec.ulaval.ca (A.D.); stephane.dubois@crchudequebec.ulaval.ca (S.D.); annie-c.c-deschesnes@crchudequebec.ulaval.ca (A.-C.C.-D.); penny.soucy@crchudequebec.ulaval.ca (P.S.); maxime.vallee@chu-lyon.fr (M.V.); frederic.fournier.4@ulaval.ca (F.F.); audrey@mims.ai (A.L.)"],["dc.contributor.affiliation","Lemaçon, Audrey; 1Genomics Center, CHU de Québec-Université Laval Research Center, 2705 Laurier Boulevard, Quebec City, QC GIV 4G2, Canada; martine.dumont@crchudequebec.ulaval.ca (M.D.); charles.joly-beauparlant@crchudequebec.ulaval.ca (C.J.-B.); arnaud.droit@crchudequebec.ulaval.ca (A.D.); stephane.dubois@crchudequebec.ulaval.ca (S.D.); annie-c.c-deschesnes@crchudequebec.ulaval.ca (A.-C.C.-D.); penny.soucy@crchudequebec.ulaval.ca (P.S.); maxime.vallee@chu-lyon.fr (M.V.); frederic.fournier.4@ulaval.ca (F.F.); audrey@mims.ai (A.L.)"],["dc.contributor.affiliation","Adank, Muriel A.; 5Family Cancer Clinic, The Netherlands Cancer Institute—Antoni van Leeuwenhoek Hospital, 1066 Amsterdam, The Netherlands; m.adank@nki.nl (M.A.A.); f.hogervorst@nki.nl (F.B.L.H.); l.vd.kolk@nki.nl (L.v.d.K.)"],["dc.contributor.affiliation","Allen, Jamie; 6Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge CB1 8RN, UK; jma@ebi.ac.uk (J.A.); mkh39@medschl.cam.ac.uk (M.K.B.); sc2017@medschl.cam.ac.uk (S.C.); paul.pharoah@medschl.cam.ac.uk (P.D.P.P.); qw232@medschl.cam.ac.uk (Q.W.); dfe20@medschl.cam.ac.uk (D.F.E.)"],["dc.contributor.affiliation","Altmüller, Janine; 7Cologne Center for Genomics (CCG), Faculty of Medicine, University Hospital Cologne, University of Cologne, 50931 Cologne, Germany; janine.altmueller@mdc-berlin.de (J.A.); holger.thiele@uni-koeln.de (H.T.)"],["dc.contributor.affiliation","Arnold, Norbert; 8Institute of Clinical Molecular Biology, Department of Gynaecology and Obstetrics, University Hospital of Schleswig-Holstein, Campus Kiel, Christian-Albrechts University Kiel, 24105 Kiel, Germany; norbert.arnold@uksh.de"],["dc.contributor.affiliation","Ausems, Margreet G. E. M.; 9Division Laboratories, Pharmacy and Biomedical Genetics, Department of Genetics, University Medical Center Utrecht, 3584 Utrecht, The Netherlands; m.g.e.m.ausems@umcutrecht.nl"],["dc.contributor.affiliation","Berutti, Riccardo; 10Institute of Human Genetics, Technische Universität München, 81675 Munich, Germany; riccardo.berutti@helmholtz-muenchen.de (R.B.); tim.strom@tum.de (T.M.S.)"],["dc.contributor.affiliation","Bolla, Manjeet K.; 6Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge CB1 8RN, UK; jma@ebi.ac.uk (J.A.); mkh39@medschl.cam.ac.uk (M.K.B.); sc2017@medschl.cam.ac.uk (S.C.); paul.pharoah@medschl.cam.ac.uk (P.D.P.P.); qw232@medschl.cam.ac.uk (Q.W.); dfe20@medschl.cam.ac.uk (D.F.E.)"],["dc.contributor.affiliation","Bull, Shelley; 11Lunenfeld-Tanenbaum Research Institute, Sinai Health System, Toronto, ON M5G 1X5, Canada; bull@lunenfeld.ca (S.B.); jessica.green@sinaihealth.ca (J.G.); gary.bader@utoronto.ca (G.D.B.); andrulis@lunenfeld.ca (I.L.A.)"],["dc.contributor.affiliation","Carvalho, Sara; 6Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge CB1 8RN, UK; jma@ebi.ac.uk (J.A.); mkh39@medschl.cam.ac.uk (M.K.B.); sc2017@medschl.cam.ac.uk (S.C.); paul.pharoah@medschl.cam.ac.uk (P.D.P.P.); qw232@medschl.cam.ac.uk (Q.W.); dfe20@medschl.cam.ac.uk (D.F.E.)"],["dc.contributor.affiliation","Cornelissen, Sten; 13Division of Molecular Pathology, The Netherlands Cancer Institute—Antoni van Leeuwenhoek Hospital, 1066 Amsterdam, The Netherlands; s.cornelissen@nki.nl (S.C.); r.keeman@nki.nl (R.K.); mk.schmidt@nki.nl (M.K.S.)"],["dc.contributor.affiliation","Dufault, Michael R.; 14Precision Medicine and Computational Biology, Sanofi Genzyme, Cambridge, MA 02142, USA; michael.dufault@sanofi.com"],["dc.contributor.affiliation","Dunning, Alison M.; 15Centre for Cancer Genetic Epidemiology, Department of Oncology, University of Cambridge, Cambridge CB1 8RN, UK; amd24@medschl.cam.ac.uk (A.M.D.); craig@srl.cam.ac.uk (C.L.); ms483@medschl.cam.ac.uk (M.S.)"],["dc.contributor.affiliation","Engel, Christoph; 16Institute for Medical Informatics, Statistics and Epidemiology, University of Leipzig, 04107 Leipzig, Germany; christoph.engel@imise.uni-leipzig.de"],["dc.contributor.affiliation","Gehrig, Andrea; 17Centre of Familial Breast and Ovarian Cancer, Department of Medical Genetics, Institute of Human Genetics, University of Würzburg, 97074 Würzburg, Germany; gehrig@biozentrum.uni-wuerzburg.de"],["dc.contributor.affiliation","Geurts-Giele, Willemina R. R.; 18Department of Clinical Genetics, Erasmus University Medical Center, 3015 Rotterdam, The Netherlands; w.geurts-giele@erasmusmc.nl"],["dc.contributor.affiliation","Gieger, Christian; 19Institute of Epidemiology, Helmholtz Zentrum München, German Research Center for Environmental Health, 85764 Neuherberg, Germany; christian.gieger@helmholtz-muenchen.de (C.G.); peters@helmholtz-muenchen.de (A.P.)"],["dc.contributor.affiliation","Green, Jessica; 11Lunenfeld-Tanenbaum Research Institute, Sinai Health System, Toronto, ON M5G 1X5, Canada; bull@lunenfeld.ca (S.B.); jessica.green@sinaihealth.ca (J.G.); gary.bader@utoronto.ca (G.D.B.); andrulis@lunenfeld.ca (I.L.A.)"],["dc.contributor.affiliation","Hackmann, Karl; 22Institute for Clinical Genetics, Faculty of Medicine Carl Gustav Carus, Technische Universität Dresden, 01307 Dresden, Germany; karl.hackmann@uniklinikum-dresden.de"],["dc.contributor.affiliation","Helmy, Mohamed; 23The Donnelly Centre, University of Toronto, Toronto, ON M5S 3E1, Canada; mohamed_helmy@bii.a-star.edu.sg"],["dc.contributor.affiliation","Hentschel, Julia; 26Institute of Human Genetics, University Leipzig, 04103 Leipzig, Germany; julia.hentschel@medizin.uni-leipzig.de"],["dc.contributor.affiliation","Hogervorst, Frans B. L.; 5Family Cancer Clinic, The Netherlands Cancer Institute—Antoni van Leeuwenhoek Hospital, 1066 Amsterdam, The Netherlands; m.adank@nki.nl (M.A.A.); f.hogervorst@nki.nl (F.B.L.H.); l.vd.kolk@nki.nl (L.v.d.K.)"],["dc.contributor.affiliation","Hollestelle, Antoinette; 27Department of Medical Oncology, Erasmus MC Cancer Institute, 3015 Rotterdam, The Netherlands; a.hollestelle@erasmusmc.nl (A.H.); m.hooning@erasmusmc.nl (M.J.H.); j.martens@erasmusmc.nl (J.W.M.M.)"],["dc.contributor.affiliation","Hooning, Maartje J.; 27Department of Medical Oncology, Erasmus MC Cancer Institute, 3015 Rotterdam, The Netherlands; a.hollestelle@erasmusmc.nl (A.H.); m.hooning@erasmusmc.nl (M.J.H.); j.martens@erasmusmc.nl (J.W.M.M.)"],["dc.contributor.affiliation","Horváth, Judit; 28Institute of Human Genetics, University of Münster, 48149 Münster, Germany; judit.horvath@ukmuenster.de"],["dc.contributor.affiliation","Ikram, M. Arfan; 29Department of Epidemiology, Erasmus MC University Medical Center, 3015 Rotterdam, The Netherlands; m.a.ikram@erasmusmc.nl"],["dc.contributor.affiliation","Kaulfuß, Silke; 30Institute of Human Genetics, University Medical Center Göttingen, 37075 Göttingen, Germany; silke.kaulfuss@med.uni-goettingen.de"],["dc.contributor.affiliation","Keeman, Renske; 13Division of Molecular Pathology, The Netherlands Cancer Institute—Antoni van Leeuwenhoek Hospital, 1066 Amsterdam, The Netherlands; s.cornelissen@nki.nl (S.C.); r.keeman@nki.nl (R.K.); mk.schmidt@nki.nl (M.K.S.)"],["dc.contributor.affiliation","Kuang, Da; 21Department of Molecular Genetics, University of Toronto, Toronto, ON M5S 1A8, Canada; kvn.kuang@mail.utoronto.ca"],["dc.contributor.affiliation","Luccarini, Craig; 15Centre for Cancer Genetic Epidemiology, Department of Oncology, University of Cambridge, Cambridge CB1 8RN, UK; amd24@medschl.cam.ac.uk (A.M.D.); craig@srl.cam.ac.uk (C.L.); ms483@medschl.cam.ac.uk (M.S.)"],["dc.contributor.affiliation","Maier, Wolfgang; 31German Center for Neurodegenerative Diseases (DZNE), Department of Neurodegenerative Diseases and Geriatric Psychiatry, Medical Faculty, University Hospital Bonn, 53127 Bonn, Germany; wolfgang.maier@ukb.uni-bonn.de"],["dc.contributor.affiliation","Martens, John W. M.; 27Department of Medical Oncology, Erasmus MC Cancer Institute, 3015 Rotterdam, The Netherlands; a.hollestelle@erasmusmc.nl (A.H.); m.hooning@erasmusmc.nl (M.J.H.); j.martens@erasmusmc.nl (J.W.M.M.)"],["dc.contributor.affiliation","Niederacher, Dieter; 32Department of Gynecology and Obstetrics, University Hospital Düsseldorf, Heinrich-Heine University Düsseldorf, 40225 Düsseldorf, Germany; niederac@med.uni-duesseldorf.de"],["dc.contributor.affiliation","Nürnberg, Peter; 33Center for Molecular Medicine Cologne (CMMC), Cologne Center for Genomics (CCG), Faculty of Medicine, University Hospital Cologne, University of Cologne, 50931 Cologne, Germany; nuernberg@uni-koeln.de"],["dc.contributor.affiliation","Ott, Claus-Eric; 34Institute of Medical Genetics and Human Genetics, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin and Berlin Institute of Health, 13353 Berlin, Germany; claus-eric.ott@charite.de"],["dc.contributor.affiliation","Peters, Annette; 19Institute of Epidemiology, Helmholtz Zentrum München, German Research Center for Environmental Health, 85764 Neuherberg, Germany; christian.gieger@helmholtz-muenchen.de (C.G.); peters@helmholtz-muenchen.de (A.P.)"],["dc.contributor.affiliation","Pharoah, Paul D. P.; 6Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge CB1 8RN, UK; jma@ebi.ac.uk (J.A.); mkh39@medschl.cam.ac.uk (M.K.B.); sc2017@medschl.cam.ac.uk (S.C.); paul.pharoah@medschl.cam.ac.uk (P.D.P.P.); qw232@medschl.cam.ac.uk (Q.W.); dfe20@medschl.cam.ac.uk (D.F.E.)"],["dc.contributor.affiliation","Ramirez, Alfredo; 36Division for Neurogenetics and Molecular Psychiatry, Medical Faculty, University of Cologne, 50937 Cologne, Germany; alfredo.ramirez@uk-koeln.de"],["dc.contributor.affiliation","Ramser, Juliane; 37Division of Gynaecology and Obstetrics, Klinikum Rechts der Isar der Technischen Universität München, 81675 Munich, Germany; juliane.ramser@mri.tum.de (J.R.); alfons.meindl@gmx.de (A.M.)"],["dc.contributor.affiliation","Riedel-Heller, Steffi; 38Institute of Social Medicine, Occupational Health and Public Health, Faculty of Medicine, University of Leipzig, 04103 Leipzig, Germany; steffi.riedel-heller@medizin.uni-leipzig.de"],["dc.contributor.affiliation","Schmidt, Gunnar; 39Institute of Human Genetics, Hannover Medical School, 30625 Hannover, Germany; schmidt.gunnar@mh-hannover.de"],["dc.contributor.affiliation","Shah, Mitul; 15Centre for Cancer Genetic Epidemiology, Department of Oncology, University of Cambridge, Cambridge CB1 8RN, UK; amd24@medschl.cam.ac.uk (A.M.D.); craig@srl.cam.ac.uk (C.L.); ms483@medschl.cam.ac.uk (M.S.)"],["dc.contributor.affiliation","Scherer, Martin; 40Department of Primary Medical Care, University Medical Center Hamburg-Eppendorf, 20246 Hamburg, Germany; m.scherer@uke.de"],["dc.contributor.affiliation","Stäbler, Antje; 41Institute of Medical Genetics and Applied Genomics, University of Tübingen, 72076 Tübingen, Germany; antje.staebler@med.uni-tuebingen.de"],["dc.contributor.affiliation","Strom, Tim M.; 10Institute of Human Genetics, Technische Universität München, 81675 Munich, Germany; riccardo.berutti@helmholtz-muenchen.de (R.B.); tim.strom@tum.de (T.M.S.)"],["dc.contributor.affiliation","Sutter, Christian; 42Institute of Human Genetics, University Hospital Heidelberg, 69120 Heidelberg, Germany; christian.sutter@med.uni-heidelberg.de"],["dc.contributor.affiliation","Thiele, Holger; 7Cologne Center for Genomics (CCG), Faculty of Medicine, University Hospital Cologne, University of Cologne, 50931 Cologne, Germany; janine.altmueller@mdc-berlin.de (J.A.); holger.thiele@uni-koeln.de (H.T.)"],["dc.contributor.affiliation","van Asperen, Christi J.; 43Department of Clinical Genetics, Leiden University Medical Center, 2333 Leiden, The Netherlands; c.j.van_asperen@lumc.nl (C.J.v.A.); r.b.van_der_luijt@lumc.nl (R.B.v.d.L.)"],["dc.contributor.affiliation","van der Kolk, Lizet; 5Family Cancer Clinic, The Netherlands Cancer Institute—Antoni van Leeuwenhoek Hospital, 1066 Amsterdam, The Netherlands; m.adank@nki.nl (M.A.A.); f.hogervorst@nki.nl (F.B.L.H.); l.vd.kolk@nki.nl (L.v.d.K.)"],["dc.contributor.affiliation","van der Luijt, Rob B.; 43Department of Clinical Genetics, Leiden University Medical Center, 2333 Leiden, The Netherlands; c.j.van_asperen@lumc.nl (C.J.v.A.); r.b.van_der_luijt@lumc.nl (R.B.v.d.L.)"],["dc.contributor.affiliation","Volk, Alexander E.; 45Institute of Human Genetics, University Medical Center Hamburg-Eppendorf, 20246 Hamburg, Germany; a.volk@uke.de"],["dc.contributor.affiliation","Wagner, Michael; 46Department of Neurodegenerative Diseases and Geriatric Psychiatry, University Hospital Bonn, 53127 Bonn, Germany; michael.wagner@ukbonn.de"],["dc.contributor.affiliation","Waisfisz, Quinten; 47Department of Human Genetics, Amsterdam UMC, Vrije Universiteit Amsterdam, 1081 Amsterdam, The Netherlands; q.waisfisz@vumc.nl"],["dc.contributor.affiliation","Wang, Qin; 6Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge CB1 8RN, UK; jma@ebi.ac.uk (J.A.); mkh39@medschl.cam.ac.uk (M.K.B.); sc2017@medschl.cam.ac.uk (S.C.); paul.pharoah@medschl.cam.ac.uk (P.D.P.P.); qw232@medschl.cam.ac.uk (Q.W.); dfe20@medschl.cam.ac.uk (D.F.E.)"],["dc.contributor.affiliation","Wang-Gohrke, Shan; 48Department of Gynaecology and Obstetrics, University of Ulm, 89081 Ulm, Germany; shan.wang-gohrke@uniklinik-ulm.de"],["dc.contributor.affiliation","Weber, Bernhard H. F.; 49Institute of Human Genetics, Regensburg University, 93053 Regensburg, Germany; bweb@klinik.uni-regensburg.de"],["dc.contributor.affiliation","Devilee, Peter; 51Department of Pathology, Department of Human Genetics, Leiden University Medical Center, 2333 Leiden, The Netherlands; p.devilee@lumc.nl"],["dc.contributor.affiliation","Tavtigian, Sean; 4Huntsman Cancer Institute, University of Utah, Salt Lake City, UT 84112, USA; sean.tavtigian@hci.utah.edu"],["dc.contributor.affiliation","Bader, Gary D.; 11Lunenfeld-Tanenbaum Research Institute, Sinai Health System, Toronto, ON M5G 1X5, Canada; bull@lunenfeld.ca (S.B.); jessica.green@sinaihealth.ca (J.G.); gary.bader@utoronto.ca (G.D.B.); andrulis@lunenfeld.ca (I.L.A.)"],["dc.contributor.affiliation","Meindl, Alfons; 37Division of Gynaecology and Obstetrics, Klinikum Rechts der Isar der Technischen Universität München, 81675 Munich, Germany; juliane.ramser@mri.tum.de (J.R.); alfons.meindl@gmx.de (A.M.)"],["dc.contributor.affiliation","Goldgar, David E.; 3Department of Dermatology, University of Utah, Salt Lake City, UT 84103, USA; bingjian.feng@hsc.utah.edu (B.-J.F.); david.goldgar@hsc.utah.edu (D.E.G.)"],["dc.contributor.affiliation","Andrulis, Irene L.; 11Lunenfeld-Tanenbaum Research Institute, Sinai Health System, Toronto, ON M5G 1X5, Canada; bull@lunenfeld.ca (S.B.); jessica.green@sinaihealth.ca (J.G.); gary.bader@utoronto.ca (G.D.B.); andrulis@lunenfeld.ca (I.L.A.)"],["dc.contributor.affiliation","Schmutzler, Rita K.; 2Center for Familial Breast and Ovarian Cancer, Center for Integrated Oncology (CIO), Faculty of Medicine and University Hospital Cologne, University of Cologne, 50937 Cologne, Germany; nana.weber-lassalle@uk-koeln.de (N.W.-L.); corinna.ernst@uk-koeln.de (C.E.); rita.schmutzler@uk-koeln.de (R.K.S.); eric.hahnen@uk-koeln.de (E.H.)"],["dc.contributor.affiliation","Easton, Douglas F.; 6Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge CB1 8RN, UK; jma@ebi.ac.uk (J.A.); mkh39@medschl.cam.ac.uk (M.K.B.); sc2017@medschl.cam.ac.uk (S.C.); paul.pharoah@medschl.cam.ac.uk (P.D.P.P.); qw232@medschl.cam.ac.uk (Q.W.); dfe20@medschl.cam.ac.uk (D.F.E.)"],["dc.contributor.affiliation","Schmidt, Marjanka K.; 13Division of Molecular Pathology, The Netherlands Cancer Institute—Antoni van Leeuwenhoek Hospital, 1066 Amsterdam, The Netherlands; s.cornelissen@nki.nl (S.C.); r.keeman@nki.nl (R.K.); mk.schmidt@nki.nl (M.K.S.)"],["dc.contributor.affiliation","Hahnen, Eric; 2Center for Familial Breast and Ovarian Cancer, Center for Integrated Oncology (CIO), Faculty of Medicine and University Hospital Cologne, University of Cologne, 50937 Cologne, Germany; nana.weber-lassalle@uk-koeln.de (N.W.-L.); corinna.ernst@uk-koeln.de (C.E.); rita.schmutzler@uk-koeln.de (R.K.S.); eric.hahnen@uk-koeln.de (E.H.)"],["dc.contributor.affiliation","Simard, Jacques; 1Genomics Center, CHU de Québec-Université Laval Research Center, 2705 Laurier Boulevard, Quebec City, QC GIV 4G2, Canada; martine.dumont@crchudequebec.ulaval.ca (M.D.); charles.joly-beauparlant@crchudequebec.ulaval.ca (C.J.-B.); arnaud.droit@crchudequebec.ulaval.ca (A.D.); stephane.dubois@crchudequebec.ulaval.ca (S.D.); annie-c.c-deschesnes@crchudequebec.ulaval.ca (A.-C.C.-D.); penny.soucy@crchudequebec.ulaval.ca (P.S.); maxime.vallee@chu-lyon.fr (M.V.); frederic.fournier.4@ulaval.ca (F.F.); audrey@mims.ai (A.L.)"],["dc.contributor.author","Dumont, Martine"],["dc.contributor.author","Weber-Lassalle, Nana"],["dc.contributor.author","Joly-Beauparlant, Charles"],["dc.contributor.author","Ernst, Corinna"],["dc.contributor.author","Droit, Arnaud"],["dc.contributor.author","Feng, Bing-Jian"],["dc.contributor.author","Dubois, Stéphane"],["dc.contributor.author","Collin-Deschesnes, Annie-Claude"],["dc.contributor.author","Soucy, Penny"],["dc.contributor.author","Vallée, Maxime"],["dc.contributor.author","Fournier, Frédéric"],["dc.contributor.author","Lemaçon, Audrey"],["dc.contributor.author","Adank, Muriel A."],["dc.contributor.author","Allen, Jamie"],["dc.contributor.author","Altmüller, Janine"],["dc.contributor.author","Arnold, Norbert"],["dc.contributor.author","Ausems, Margreet G. E. M."],["dc.contributor.author","Berutti, Riccardo"],["dc.contributor.author","Bolla, Manjeet K."],["dc.contributor.author","Bull, Shelley"],["dc.contributor.author","Carvalho, Sara"],["dc.contributor.author","Cornelissen, Sten"],["dc.contributor.author","Dufault, Michael R."],["dc.contributor.author","Dunning, Alison M."],["dc.contributor.author","Engel, Christoph"],["dc.contributor.author","Gehrig, Andrea"],["dc.contributor.author","Geurts-Giele, Willemina R. R."],["dc.contributor.author","Gieger, Christian"],["dc.contributor.author","Green, Jessica"],["dc.contributor.author","Hackmann, Karl"],["dc.contributor.author","Helmy, Mohamed"],["dc.contributor.author","Hentschel, Julia"],["dc.contributor.author","Hogervorst, Frans B. L."],["dc.contributor.author","Hollestelle, Antoinette"],["dc.contributor.author","Hooning, Maartje J."],["dc.contributor.author","Horváth, Judit"],["dc.contributor.author","Ikram, M. Arfan"],["dc.contributor.author","Kaulfuß, Silke"],["dc.contributor.author","Keeman, Renske"],["dc.contributor.author","Kuang, Da"],["dc.contributor.author","Luccarini, Craig"],["dc.contributor.author","Maier, Wolfgang"],["dc.contributor.author","Martens, John W. M."],["dc.contributor.author","Niederacher, Dieter"],["dc.contributor.author","Nürnberg, Peter"],["dc.contributor.author","Ott, Claus-Eric"],["dc.contributor.author","Peters, Annette"],["dc.contributor.author","Pharoah, Paul D. P."],["dc.contributor.author","Ramirez, Alfredo"],["dc.contributor.author","Ramser, Juliane"],["dc.contributor.author","Riedel-Heller, Steffi"],["dc.contributor.author","Schmidt, Gunnar"],["dc.contributor.author","Shah, Mitul"],["dc.contributor.author","Scherer, Martin"],["dc.contributor.author","Stäbler, Antje"],["dc.contributor.author","Strom, Tim M."],["dc.contributor.author","Sutter, Christian"],["dc.contributor.author","Thiele, Holger"],["dc.contributor.author","van Asperen, Christi J."],["dc.contributor.author","van der Kolk, Lizet"],["dc.contributor.author","van der Luijt, Rob B."],["dc.contributor.author","Volk, Alexander E."],["dc.contributor.author","Wagner, Michael"],["dc.contributor.author","Waisfisz, Quinten"],["dc.contributor.author","Wang, Qin"],["dc.contributor.author","Wang-Gohrke, Shan"],["dc.contributor.author","Weber, Bernhard H. F."],["dc.contributor.author","Devilee, Peter"],["dc.contributor.author","Tavtigian, Sean"],["dc.contributor.author","Bader, Gary D."],["dc.contributor.author","Meindl, Alfons"],["dc.contributor.author","Goldgar, David E."],["dc.contributor.author","Andrulis, Irene L."],["dc.contributor.author","Schmutzler, Rita K."],["dc.contributor.author","Easton, Douglas F."],["dc.contributor.author","Schmidt, Marjanka K."],["dc.contributor.author","Hahnen, Eric"],["dc.contributor.author","Simard, Jacques"],["dc.date.accessioned","2022-08-04T08:22:05Z"],["dc.date.available","2022-08-04T08:22:05Z"],["dc.date.issued","2022-07-11"],["dc.date.updated","2022-08-03T11:52:48Z"],["dc.description.abstract","Genetic variants explaining approximately 40% of familial breast cancer risk have been identified, thus leaving a significant fraction of the heritability of this disease still unexplained. The exact nature of this missing fraction is unknown; more extensive sequencing efforts could potentially identify new moderate-penetrance breast cancer risk alleles. The aim of this study was to perform a large-scale whole-exome sequencing study, followed by a targeted validation, in breast cancer patients and healthy women of European descent. We identified 20 novel genes with modest evidence of association (p-value < 0.05) for either overall or subtype-specific breast cancer; however, much larger studies are needed to confirm the exact role of these genes in susceptibility to breast cancer.\r\n \r\n \r\n Abstract\r\n Rare variants in at least 10 genes, including BRCA1, BRCA2, PALB2, ATM, and CHEK2, are associated with increased risk of breast cancer; however, these variants, in combination with common variants identified through genome-wide association studies, explain only a fraction of the familial aggregation of the disease. To identify further susceptibility genes, we performed a two-stage whole-exome sequencing study. In the discovery stage, samples from 1528 breast cancer cases enriched for breast cancer susceptibility and 3733 geographically matched unaffected controls were sequenced. Using five different filtering and gene prioritization strategies, 198 genes were selected for further validation. These genes, and a panel of 32 known or suspected breast cancer susceptibility genes, were assessed in a validation set of 6211 cases and 6019 controls for their association with risk of breast cancer overall, and by estrogen receptor (ER) disease subtypes, using gene burden tests applied to loss-of-function and rare missense variants. Twenty genes showed nominal evidence of association (p-value < 0.05) with either overall or subtype-specific breast cancer. Our study had the statistical power to detect susceptibility genes with effect sizes similar to ATM, CHEK2, and PALB2, however, it was underpowered to identify genes in which susceptibility variants are rarer or confer smaller effect sizes. Larger sample sizes would be required in order to identify such genes."],["dc.description.sponsorship","Genome Canada"],["dc.description.sponsorship","Canadian Institutes of Health Research"],["dc.description.sponsorship","Genome Quebec"],["dc.description.sponsorship","Quebec Breast Cancer Foundation"],["dc.description.sponsorship","Ministère de l’Économie, de la Science et de l’Innovation du Québec"],["dc.description.sponsorship","U.S. National Institutes of Health, National Center for Research Resources"],["dc.identifier.doi","10.3390/cancers14143363"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/112620"],["dc.language.iso","en"],["dc.relation.eissn","2072-6694"],["dc.rights","CC BY 4.0"],["dc.title","Uncovering the Contribution of Moderate-Penetrance Susceptibility Genes to Breast Cancer by Whole-Exome Sequencing and Targeted Enrichment Sequencing of Candidate Genes in Women of European Ancestry"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.subtype","original_ja"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.artnumber","55"],["dc.bibliographiccitation.issue","1"],["dc.bibliographiccitation.journal","Breast Cancer Research"],["dc.bibliographiccitation.volume","21"],["dc.contributor.author","Weber-Lassalle, Nana"],["dc.contributor.author","Borde, Julika"],["dc.contributor.author","Weber-Lassalle, Konstantin"],["dc.contributor.author","Horváth, Judit"],["dc.contributor.author","Niederacher, Dieter"],["dc.contributor.author","Arnold, Norbert"],["dc.contributor.author","Kaulfuß, Silke"],["dc.contributor.author","Ernst, Corinna"],["dc.contributor.author","Paul, Victoria G."],["dc.contributor.author","Honisch, Ellen"],["dc.contributor.author","Klaschik, Kristina"],["dc.contributor.author","Volk, Alexander E."],["dc.contributor.author","Kubisch, Christian"],["dc.contributor.author","Rapp, Steffen"],["dc.contributor.author","Lichey, Nadine"],["dc.contributor.author","Altmüller, Janine"],["dc.contributor.author","Lepkes, Louisa"],["dc.contributor.author","Pohl-Rescigno, Esther"],["dc.contributor.author","Thiele, Holger"],["dc.contributor.author","Nürnberg, Peter"],["dc.contributor.author","Larsen, Mirjam"],["dc.contributor.author","Richters, Lisa"],["dc.contributor.author","Rhiem, Kerstin"],["dc.contributor.author","Wappenschmidt, Barbara"],["dc.contributor.author","Engel, Christoph"],["dc.contributor.author","Meindl, Alfons"],["dc.contributor.author","Schmutzler, Rita K."],["dc.contributor.author","Hahnen, Eric"],["dc.contributor.author","Hauke, Jan"],["dc.date.accessioned","2019-07-09T11:51:25Z"],["dc.date.available","2019-07-09T11:51:25Z"],["dc.date.issued","2019"],["dc.description.abstract","BACKGROUND: The role of the BARD1 gene in breast cancer (BC) and ovarian cancer (OC) predisposition remains elusive, as published case-control investigations have revealed controversial results. We aimed to assess the role of deleterious BARD1 germline variants in BC/OC predisposition in a sample of 4920 BRCA1/2-negative female BC/OC index patients of the German Consortium for Hereditary Breast and Ovarian Cancer (GC-HBOC). METHODS: A total of 4469 female index patients with BC, 451 index patients with OC, and 2767 geographically matched female control individuals were screened for loss-of-function (LoF) mutations and potentially damaging rare missense variants in BARD1. All patients met the inclusion criteria of the GC-HBOC for germline testing and reported at least one relative with BC or OC. Additional control datasets (Exome Aggregation Consortium, ExAC; Fabulous Ladies Over Seventy, FLOSSIES) were included for the calculation of odds ratios (ORs). RESULTS: We identified LoF variants in 23 of 4469 BC index patients (0.51%) and in 36 of 37,265 control individuals (0.10%), resulting in an OR of 5.35 (95% confidence interval [CI] = 3.17-9.04; P < 0.00001). BARD1-mutated BC index patients showed a significantly younger mean age at first diagnosis (AAD; 42.3 years, range 24-60 years) compared with the overall study sample (48.6 years, range 17-92 years; P = 0.00347). In the subgroup of BC index patients with an AAD < 40 years, an OR of 12.04 (95% CI = 5.78-25.08; P < 0.00001) was observed. An OR of 7.43 (95% CI = 4.26-12.98; P < 0.00001) was observed when stratified for an AAD < 50 years. LoF variants in BARD1 were not significantly associated with BC in the subgroup of index patients with an AAD ≥ 50 years (OR = 2.29; 95% CI = 0.82-6.45; P = 0.11217). Overall, rare and predicted damaging BARD1 missense variants were significantly more prevalent in BC index patients compared with control individuals (OR = 2.15; 95% CI = 1.26-3.67; P = 0.00723). Neither LoF variants nor predicted damaging rare missense variants in BARD1 were identified in 451 familial index patients with OC. CONCLUSIONS: Due to the significant association of germline LoF variants in BARD1 with early-onset BC, we suggest that intensified BC surveillance programs should be offered to women carrying pathogenic BARD1 gene variants."],["dc.identifier.doi","10.1186/s13058-019-1137-9"],["dc.identifier.pmid","31036035"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/16123"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/59944"],["dc.language.iso","en"],["dc.notes.intern","Merged from goescholar"],["dc.rights","CC BY 4.0"],["dc.rights.uri","https://creativecommons.org/licenses/by/4.0"],["dc.subject.ddc","610"],["dc.title","Germline loss-of-function variants in the BARD1 gene are associated with early-onset familial breast cancer but not ovarian cancer"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","1557"],["dc.bibliographiccitation.issue","9"],["dc.bibliographiccitation.journal","Human Mutation"],["dc.bibliographiccitation.lastpage","1578"],["dc.bibliographiccitation.volume","40"],["dc.contributor.author","Parsons, Michael T."],["dc.contributor.author","Tudini, Emma"],["dc.contributor.author","Li, Hongyan"],["dc.contributor.author","Hahnen, Eric"],["dc.contributor.author","Wappenschmidt, Barbara"],["dc.contributor.author","Feliubadaló, Lidia"],["dc.contributor.author","Aalfs, Cora M."],["dc.contributor.author","Agata, Simona"],["dc.contributor.author","Aittomäki, Kristiina"],["dc.contributor.author","Alducci, Elisa"],["dc.contributor.author","Kaulfuß, Silke"],["dc.contributor.author","Engel, Christoph"],["dc.contributor.author","Spurdle, Amanda B."],["dc.date.accessioned","2019-12-02T14:12:29Z"],["dc.date.accessioned","2021-10-27T13:21:42Z"],["dc.date.available","2019-12-02T14:12:29Z"],["dc.date.available","2021-10-27T13:21:42Z"],["dc.date.issued","2019"],["dc.description.abstract","The multifactorial likelihood analysis method has demonstrated utility for quantitative assessment of variant pathogenicity for multiple cancer syndrome genes. Independent data types currently incorporated in the model for assessing BRCA1 and BRCA2 variants include clinically calibrated prior probability of pathogenicity based on variant location and bioinformatic prediction of variant effect, co-segregation, family cancer history profile, co-occurrence with a pathogenic variant in the same gene, breast tumor pathology, and case-control information. Research and clinical data for multifactorial likelihood analysis were collated for 1,395 BRCA1/2 predominantly intronic and missense variants, enabling classification based on posterior probability of pathogenicity for 734 variants: 447 variants were classified as (likely) benign, and 94 as (likely) pathogenic; and 248 classifications were new or considerably altered relative to ClinVar submissions. Classifications were compared with information not yet included in the likelihood model, and evidence strengths aligned to those recommended for ACMG/AMP classification codes. Altered mRNA splicing or function relative to known nonpathogenic variant controls were moderately to strongly predictive of variant pathogenicity. Variant absence in population datasets provided supporting evidence for variant pathogenicity. These findings have direct relevance for BRCA1 and BRCA2 variant evaluation, and justify the need for gene-specific calibration of evidence types used for variant classification."],["dc.identifier.doi","10.1002/humu.23818"],["dc.identifier.eissn","1098-1004"],["dc.identifier.issn","1059-7794"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/16801"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/92041"],["dc.language.iso","en"],["dc.notes.intern","Migrated from goescholar"],["dc.relation.eissn","1098-1004"],["dc.relation.issn","1059-7794"],["dc.relation.orgunit","Universitätsmedizin Göttingen"],["dc.rights","CC BY 4.0"],["dc.rights.uri","https://creativecommons.org/licenses/by/4.0"],["dc.subject.ddc","610"],["dc.title","Large scale multifactorial likelihood quantitative analysis of BRCA1 and BRCA2 variants: An ENIGMA resource to support clinical variant classification"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.artnumber","265"],["dc.bibliographiccitation.issue","1"],["dc.bibliographiccitation.journal","BMC Cancer"],["dc.bibliographiccitation.volume","18"],["dc.contributor.author","Engel, Christoph"],["dc.contributor.author","Rhiem, Kerstin"],["dc.contributor.author","Hahnen, Eric"],["dc.contributor.author","Loibl, Sibylle"],["dc.contributor.author","Weber, Karsten E."],["dc.contributor.author","Seiler, Sabine"],["dc.contributor.author","Zachariae, Silke"],["dc.contributor.author","Hauke, Jan"],["dc.contributor.author","Wappenschmidt, Barbara"],["dc.contributor.author","Waha, Anke"],["dc.contributor.author","Blümcke, Britta"],["dc.contributor.author","Kiechle, Marion"],["dc.contributor.author","Meindl, Alfons"],["dc.contributor.author","Niederacher, Dieter"],["dc.contributor.author","Bartram, Claus R."],["dc.contributor.author","Speiser, Dorothee"],["dc.contributor.author","Schlegelberger, Brigitte"],["dc.contributor.author","Arnold, Norbert"],["dc.contributor.author","Wieacker, Peter"],["dc.contributor.author","Leinert, Elena"],["dc.contributor.author","Gehrig, Andrea"],["dc.contributor.author","Briest, Susanne"],["dc.contributor.author","Kast, Karin"],["dc.contributor.author","Riess, Olaf"],["dc.contributor.author","Emons, Günter"],["dc.contributor.author","Weber, Bernhard H. F."],["dc.contributor.author","Engel, Jutta"],["dc.contributor.author","Schmutzler, Rita K."],["dc.date.accessioned","2020-12-10T18:38:53Z"],["dc.date.available","2020-12-10T18:38:53Z"],["dc.date.issued","2018"],["dc.description.abstract","Abstract Background There is no international consensus up to which age women with a diagnosis of triple-negative breast cancer (TNBC) and no family history of breast or ovarian cancer should be offered genetic testing for germline BRCA1 and BRCA2 (gBRCA) mutations. Here, we explored the association of age at TNBC diagnosis with the prevalence of pathogenic gBRCA mutations in this patient group. Methods The study comprised 802 women (median age 40 years, range 19–76) with oestrogen receptor, progesterone receptor, and human epidermal growth factor receptor type 2 negative breast cancers, who had no relatives with breast or ovarian cancer. All women were tested for pathogenic gBRCA mutations. Logistic regression analysis was used to explore the association between age at TNBC diagnosis and the presence of a pathogenic gBRCA mutation. Results A total of 127 women with TNBC (15.8%) were gBRCA mutation carriers (BRCA1: n = 118, 14.7%; BRCA2: n = 9, 1.1%). The mutation prevalence was 32.9% in the age group 20–29 years compared to 6.9% in the age group 60–69 years. Logistic regression analysis revealed a significant increase of mutation frequency with decreasing age at diagnosis (odds ratio 1.87 per 10 year decrease, 95%CI 1.50–2.32, p < 0.001). gBRCA mutation risk was predicted to be > 10% for women diagnosed below approximately 50 years. Conclusions Based on the general understanding that a heterozygous mutation probability of 10% or greater justifies gBRCA mutation screening, women with TNBC diagnosed before the age of 50 years and no familial history of breast and ovarian cancer should be tested for gBRCA mutations. In Germany, this would concern approximately 880 women with newly diagnosed TNBC per year, of whom approximately 150 are expected to be identified as carriers of a pathogenic gBRCA mutation."],["dc.identifier.doi","10.1186/s12885-018-4029-y"],["dc.identifier.eissn","1471-2407"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/15130"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/77471"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-354"],["dc.notes.intern","Merged from goescholar"],["dc.publisher","BioMed Central"],["dc.rights","CC BY 4.0"],["dc.rights.uri","https://creativecommons.org/licenses/by/4.0"],["dc.title","Prevalence of pathogenic BRCA1/2 germline mutations among 802 women with unilateral triple-negative breast cancer without family cancer history"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.artnumber","e0187015"],["dc.bibliographiccitation.issue","10"],["dc.bibliographiccitation.journal","PloS one"],["dc.bibliographiccitation.volume","12"],["dc.contributor.author","Schädler, Dirk"],["dc.contributor.author","Pausch, Christine"],["dc.contributor.author","Heise, Daniel"],["dc.contributor.author","Meier-Hellmann, Andreas"],["dc.contributor.author","Brederlau, Jörg"],["dc.contributor.author","Weiler, Norbert"],["dc.contributor.author","Marx, Gernot"],["dc.contributor.author","Putensen, Christian"],["dc.contributor.author","Spies, Claudia"],["dc.contributor.author","Jörres, Achim"],["dc.contributor.author","Quintel, Michael"],["dc.contributor.author","Engel, Christoph"],["dc.contributor.author","Kellum, John A."],["dc.contributor.author","Kuhlmann, Martin K."],["dc.date.accessioned","2019-07-09T11:44:41Z"],["dc.date.available","2019-07-09T11:44:41Z"],["dc.date.issued","2017"],["dc.description.abstract","OBJECTIVE: We report on the effect of hemoadsorption therapy to reduce cytokines in septic patients with respiratory failure. METHODS: This was a randomized, controlled, open-label, multicenter trial. Mechanically ventilated patients with severe sepsis or septic shock and acute lung injury or acute respiratory distress syndrome were eligible for study inclusion. Patients were randomly assigned to either therapy with CytoSorb hemoperfusion for 6 hours per day for up to 7 consecutive days (treatment), or no hemoperfusion (control). Primary outcome was change in normalized IL-6-serum concentrations during study day 1 and 7. RESULTS: 97 of the 100 randomized patients were analyzed. We were not able to detect differences in systemic plasma IL-6 levels between the two groups (n = 75; p = 0.15). Significant IL-6 elimination, averaging between 5 and 18% per blood pass throughout the entire treatment period was recorded. In the unadjusted analysis, 60-day-mortality was significantly higher in the treatment group (44.7%) compared to the control group (26.0%; p = 0.039). The proportion of patients receiving renal replacement therapy at the time of enrollment was higher in the treatment group (31.9%) when compared to the control group (16.3%). After adjustment for patient morbidity and baseline imbalances, no association of hemoperfusion with mortality was found (p = 0.19). CONCLUSIONS: In this patient population with predominantly septic shock and multiple organ failure, hemoadsorption removed IL-6 but this did not lead to lower plasma IL-6-levels. We did not detect statistically significant differences in the secondary outcomes multiple organ dysfunction score, ventilation time and time course of oxygenation."],["dc.identifier.doi","10.1371/journal.pone.0187015"],["dc.identifier.pmid","29084247"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/14865"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/59065"],["dc.language.iso","en"],["dc.notes.intern","Merged from goescholar"],["dc.relation.issn","1932-6203"],["dc.rights","CC BY 4.0"],["dc.rights.uri","https://creativecommons.org/licenses/by/4.0"],["dc.subject.ddc","610"],["dc.subject.mesh","Aged"],["dc.subject.mesh","Cytokines"],["dc.subject.mesh","Female"],["dc.subject.mesh","Hemoperfusion"],["dc.subject.mesh","Humans"],["dc.subject.mesh","Interleukin-6"],["dc.subject.mesh","Male"],["dc.subject.mesh","Middle Aged"],["dc.subject.mesh","Sepsis"],["dc.title","The effect of a novel extracorporeal cytokine hemoadsorption device on IL-6 elimination in septic patients: A randomized controlled trial."],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","125"],["dc.bibliographiccitation.issue","2"],["dc.bibliographiccitation.journal","New England Journal of Medicine"],["dc.bibliographiccitation.lastpage","139"],["dc.bibliographiccitation.volume","358"],["dc.contributor.author","Brunkhorst, Frank M."],["dc.contributor.author","Engel, Christoph"],["dc.contributor.author","Bloos, Frank"],["dc.contributor.author","Meier-Hellmann, Andreas"],["dc.contributor.author","Ragaller, Max"],["dc.contributor.author","Weiler, Norbert"],["dc.contributor.author","Moerer, Onnen"],["dc.contributor.author","Gruendling, Matthias"],["dc.contributor.author","Oppert, Michael"],["dc.contributor.author","Grond, Stefan"],["dc.contributor.author","Olthoff, Derk"],["dc.contributor.author","Jaschinski, Ulrich"],["dc.contributor.author","John, Stefan"],["dc.contributor.author","Rossaint, Rolf"],["dc.contributor.author","Welte, Tobias"],["dc.contributor.author","Schaefer, Martin"],["dc.contributor.author","Kern, Peter"],["dc.contributor.author","Kuhnt, Evelyn"],["dc.contributor.author","Kiehntopf, Michael"],["dc.contributor.author","Hartog, Christiane"],["dc.contributor.author","Natanson, Charles"],["dc.contributor.author","Loeffler, Markus"],["dc.contributor.author","Reinhart, Konrad"],["dc.date.accessioned","2018-11-07T11:19:10Z"],["dc.date.available","2018-11-07T11:19:10Z"],["dc.date.issued","2008"],["dc.description.abstract","Background: The role of intensive insulin therapy in patients with severe sepsis is uncertain. Fluid resuscitation improves survival among patients with septic shock, but evidence is lacking to support the choice of either crystalloids or colloids. Methods: In a multicenter, two-by-two factorial trial, we randomly assigned patients with severe sepsis to receive either intensive insulin therapy to maintain euglycemia or conventional insulin therapy and either 10% pentastarch, a low-molecular-weight hydroxyethyl starch (HES 200/0.5), or modified Ringer's lactate for fluid resuscitation. The rate of death at 28 days and the mean score for organ failure were coprimary end points. Results: The trial was stopped early for safety reasons. Among 537 patients who could be evaluated, the mean morning blood glucose level was lower in the intensive-therapy group (112 mg per deciliter [6.2 mmol per liter]) than in the conventional-therapy group (151 mg per deciliter [8.4 mmol per liter], P<0.001). However, at 28 days, there was no significant difference between the two groups in the rate of death or the mean score for organ failure. The rate of severe hypoglycemia (glucose level, <= 40 mg per deciliter [2.2 mmol per liter]) was higher in the intensive-therapy group than in the conventional-therapy group (17.0% vs. 4.1%, P<0.001), as was the rate of serious adverse events (10.9% vs. 5.2%, P=0.01). HES therapy was associated with higher rates of acute renal failure and renal-replacement therapy than was Ringer's lactate. Conclusions: The use of intensive insulin therapy placed critically ill patients with sepsis at increased risk for serious adverse events related to hypoglycemia. As used in this study, HES was harmful, and its toxicity increased with accumulating doses. (ClinicalTrials.gov number, NCT00135473.)."],["dc.identifier.doi","10.1056/NEJMoa070716"],["dc.identifier.isi","000252204200004"],["dc.identifier.pmid","18184958"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/6229"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/55209"],["dc.notes.intern","Merged from goescholar"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Massachusetts Medical Soc"],["dc.relation.issn","0028-4793"],["dc.rights","Goescholar"],["dc.rights.uri","https://goescholar.uni-goettingen.de/licenses"],["dc.title","Intensive insulin therapy and pentastarch resuscitation in severe sepsis"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]